Our supporters have funded research into Crohn’s Disease and Ulcerative Colitis for almost 40 years. This has already led to innovative research into the conditions, and we have big plans for the future.
From uncovering the causes, understanding and improving treatments, and providing greater support for people to live better with their symptoms, this research is making an incredible difference.
Together, we want to improve the quality of life for everyone living with Crohn’s and Colitis, and end the stigma surrounding the disease – and the psychological impact this can cause.
Of all the conditions that we treat within Crohn’s disease and Colitis, acute severe Colitis is still one area which desperately needs improvement. It’s very important that we try and use existing treatments in a better way.
Acute severe Ulcerative Colitis (ASUC) is a life-threatening condition that requires urgent treatment with steroids.
But, 40% of people do not respond to the steroid treatment and need further rescue treatment with infliximab to avoid emergency surgery to remove their bowel (colectomy).
Unfortunately, 30% of people also fail to respond to infliximab and go on to need an emergency colectomy.
Dr Subramanian’s study will investigate the pharmacokinetics of infliximab in people with ASUC. Researchers will take blood and stool samples and measure the amount of infliximab at different time points after treatment.
They will compare this to how severe the patient’s Ulcerative Colitis is by measuring their clinical symptoms and markers of inflammation.
This will allow the researchers to find the minimum amount of infliximab that needs to be in the blood to make sure the treatment works. The researchers will use this information to create a new test that can be used in the clinic.
There has never been a more important time to support research into Crohn’s and Colitis.
Please help us create a world free from Crohn’s and Colitis by entering the 2019 Raffle for Research today.